Blood Reviews
Volume 22, Issue 6 , Pages 303-309 , November 2008

Frontline treatment of multiple myeloma in elderly patients

  • Philippe Moreau

      Affiliations

    • Hematology Department, University Hospital Hôtel-Dieu, Place A.Ricordeau, 44093 Nantes cedex, France
    • Corresponding Author InformationCorresponding author. Tel.: +33 240083271; fax: +33 240083250.
    • ,
  • Cyrille Hulin

      Affiliations

    • Hematology Department, University Hospital Brabois, Route de Neufchâteau, 54000 Nancy, France
    • Tel.: +33 383153599; fax: +33 383153558.
    • ,
  • Thierry Facon

      Affiliations

    • Hematology Department, University Hospital Huriez, Place de Verdun, 59037 Lille cedex, France
    • Tel.: +33 320444290; fax: +33 320444094.

References 

  1. Alexanian R, Haut A, Khan AU, et al. Treatment for multiple myeloma. Combination chemotherapy with different dose regimens. JAMA. 1969;208:1680–1685
  2. Bataille R, Harousseau JL. Multiple myeloma. New Engl J Med. 1997;336:1657–1664
  3. Kyle RA, Rajkumar SV. Multiple myeloma. Blood. 2008;111:2962–2972
  4. Myeloma Trialists’ Collaborative Group. Combination chemotherapy versus melphalan and prednisone as treatment for multiple myeloma: an overview of 6633 patients from 27 randomized trials. J Clin Oncol 1998;16:3832–42.
  5. Facon T, Mary JY, Pegourié B, et al. Dexamethasone-based regimens versus melphalan-prednisone for elderly multiple myeloma patients ineligible for high-dose therapy. Blood. 2006;107:1292–1298
  6. Attal M, Harousseau JL, Stoppa AM, et al. N Engl J Med. 1996;335:91–97
  7. Child JA, Morgan GJ, Davies FE, et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med. 2003;348:1875–1883
  8. Palumbo A, Triolo S, Argentino C, et al. Dose-intensive melphalan with stem cell support (mel100) is superior to standard treatment in elderly myeloma patients. Blood. 1999;94:1248–1253
  9. Palumbo A, Bringhen S, Petrucci MT, et al. Intermediate-dose melphalan melphalan improves survival of myeloma patients aged 50–70: results of a randomized controlled trial. Blood. 2004;104:3052–3057
  10. Palumbo A, Bertola A, Musto P, et al. Oral melphalan, prednisone and thalidomide for newly diagnosed patients with myeloma. Cancer. 2005;104:1428–1433
  11. Palumbo A, Bringhen S, Caravita T, et al. Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial. Lancet. 2006;367:825–831
  12. Facon T, Mary JY, Hulin C, et al. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM99-06): a randomised trial. Lancet. 2007;370:1209–1218
  13. Hulin C, Virion J, Leleu X, et al. Melphalan–prednisone–thalidomide (MPT) demonstrates a significant survival advantage in elderly patients ⩾75 years with multiple myeloma compared with melphalan-prednisone (MP) in a randomized, double-blind, placebo-controlled trial, IFM 01/01. Blood. 2007;110:31a;[abstract 75]
  14. Palumbo A, Boccadoro M. A new standard of care for elderly patients with myeloma. Lancet. 2007;370:1191–1192
  15. Waage A, Gimsing P, Juliusson G, Turesson I, Fayers P. Melphalan–prednisone–thalidomide to newly diagnosed patients with multiple myeloma: a placebo controlled randomised phase 3 trial. Blood. 2007;110:32a
  16. Palumbo A, Rajkumar SV, Dimopoulos MA, et al. Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma. Leukemia. 2008;22:414–423
  17. Palumbo A, Facon T, Sonneveld P et al. Thalidomide for treatment of multiple myeloma : 10 years later. Blood 2008 Feb1 [Epub ahead of print].
  18. Mitsiades N, Mitsiades CS, Richardson PG, et al. The proteasome inhibitor PS-341 markedly enhances sensitivity of multiple myeloma tumor cells to chemotherapeutic agents. Clin Cancer Res. 2003;9:1136–1144
  19. Berenson JR, Yang HH, Sadler K, et al. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma. J Clin Oncol. 2006;24:937–944
  20. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study. Blood. 2006;108:2165–2172
  21. Mateos MV, Hernandez JM, Hernandez MT, et al. Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: updated time-to-events results and prognostic factors for time to progression. Haematologica. 2008;93:560–565
  22. San Miguel JF, Schlag R, Khuageva N, et al. MMY-3002: a phase 3 study comparing bortezomib–melphalan–prednisone (VMP) with melphalan–prednisone (MP) in newly diagnosed multiple myeloma. Blood. 2007;110:31a;[abstract 76]
  23. Palumbo A, Falco P, Corradini P, et al. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA – Italian Multiple Myeloma Network. J Clin Oncol. 2007;25:4459–4465
  24. Rajkumar SV, Blood E, Vesole D, Fonseca R, Greipp PR. Phase III clinical trial of thalidomide plus dexamethasone compared with dexamethasone alone in newly diagnosed multiple myeloma: a clinical trial coordinated by the Eastern Cooperative Oncology Group. J Clin Oncol. 2006;24:431–436
  25. Rajkumar SV, Rosinol L, Hussein M et al. Multicenter, randomized, double-blind, placebo-controlled study of thalidomide plus dexamethasone compared with dexamethasone as initial therapy for newly diagnosed multiple myeloma. J Clin Oncol 2008 Mar 24 [Epub ahead of print].
  26. Ludwig H, Tothova E, Hajek R, et al. Thalidomide–dexamethasone vs melphalan–prednisone as first line treatment and thalidomide-Interferon maintenance therapy in elderly patients with multiple myeloma. Blood. 2007;110:163a;[abstract 529]
  27. Rajkumar SV, Hayman SR, Lacy MQ, et al. Combination therapy with lenalidomide plus dexamethasone for newly diagnosed myeloma. Blood. 2005;106:4050–4053
  28. Lacy M, Gertz M, Dispenzieri A, et al. Long-term results of response to therapy, time to progression, and survival with lenalidomide plus dexamethasone in newly diagnosed myeloma. Mayo Clin Proc. 2007;82:1179–1184
  29. Rajkumar SV, Jacobus S, Callander N, et al. A randomized trial of lenalidomide plus high-dose dexamethasone (RD) versus lenalidomide plus low-dose dexamethasone (Rd) in newly diagnosed multiple myeloma (E4A03): a trial coordinated by the Eastern Cooperative Oncology Group. Blood. 2007;110:31a;[abstract 74]

PII: S0268-960X(08)00037-4

doi: 10.1016/j.blre.2008.04.002

Blood Reviews
Volume 22, Issue 6 , Pages 303-309 , November 2008

Article Tools